These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15069793)

  • 1. Competition propping up. Second drug-eluting stent will be cheaper, plentiful.
    Becker C
    Mod Healthc; 2004 Mar; 34(11):12. PubMed ID: 15069793
    [No Abstract]   [Full Text] [Related]  

  • 2. Welcome drop seen in stent prices.
    Hosp Mater Manage; 2006 Jul; 31(7):1, 5-6. PubMed ID: 16871664
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug-eluting stent prices steady, usage declined over past several months.
    Hosp Mater Manage; 2007 Jun; 32(6):1, 5-8. PubMed ID: 17612009
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessing the impact of drug-eluting stents. Hospitals must be prepared to absorb a potentially negative financial impact.
    Pfeiffer H
    Healthc Exec; 2003; 18(4):60-1. PubMed ID: 12841062
    [No Abstract]   [Full Text] [Related]  

  • 5. Market briefing: 'dollars and stents': new technology will have major impact on heart care.
    Russ Coiles Health Trends; 2002 Dec; 15(2):11-2. PubMed ID: 12536884
    [No Abstract]   [Full Text] [Related]  

  • 6. Price survey. Stent prices expected to decline.
    Hosp Mater Manage; 2001 Sep; 26(9):1, 12-3. PubMed ID: 11552558
    [No Abstract]   [Full Text] [Related]  

  • 7. More stent problems. Boston Scientific recall could drive business to J&J.
    Becker C
    Mod Healthc; 2004 Jul; 34(30):17-9. PubMed ID: 15301058
    [No Abstract]   [Full Text] [Related]  

  • 8. One-year clinical results and total costs of drug-eluting stents implantation in multivessel coronary artery disease.
    Varani E; Balducelli M; Vecchi G; Aquilina M; Maresta A
    J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):596-601. PubMed ID: 17667030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.
    Cohen DJ; Bakhai A; Shi C; Githiora L; Lavelle T; Berezin RH; Leon MB; Moses JW; Carrozza JP; Zidar JP; Kuntz RE;
    Circulation; 2004 Aug; 110(5):508-14. PubMed ID: 15262844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stent wars. Guidant beats back market leader Johnson & Johnson with new device.
    Hensley S
    Mod Healthc; 1998 Jan; 28(2):49. PubMed ID: 10175911
    [No Abstract]   [Full Text] [Related]  

  • 11. A proactive approach to reimbursement in the era of drug-eluting stents.
    Richner R
    J Cardiovasc Manag; 2002; 13(5):32-3. PubMed ID: 12412361
    [No Abstract]   [Full Text] [Related]  

  • 12. Price survey. Stent prices down, but not enough.
    Hosp Mater Manage; 1999 Apr; 24(4):1, 13-5. PubMed ID: 10351487
    [No Abstract]   [Full Text] [Related]  

  • 13. [Potential impact of drug-eluting stents in Sicily: results from a multicenter survey and cost-benefit analysis of drug-eluting stents versus bare metal stents].
    Gulizia M; Martelli E; Tamburino C; Tolaro S; Frasheri A; Giambanco F; Grassi R; Fiscella A; Milazzo D
    Ital Heart J Suppl; 2004 Aug; 5(8):630-8. PubMed ID: 15554018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-eluting stents.
    Cohen DJ; Bakhai A
    CMAJ; 2007 May; 176(11):1612. PubMed ID: 17515592
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug-eluting stents.
    Rinfret S; Schampaert E
    CMAJ; 2007 May; 176(11):1611-2. PubMed ID: 17515589
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of the Taxus paclitaxel-eluting stent in the Swedish healthcare system.
    Ekman M; Sjögren I; James S
    Scand Cardiovasc J; 2006 Feb; 40(1):17-24. PubMed ID: 16448993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac relief. Stent prices could drop with FDA approvals ahead.
    Hensley S
    Mod Healthc; 1997 Jul; 27(28):86. PubMed ID: 10168525
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.
    Tamburino C; Barbagallo R; Capodanno D; di Matteo S; Colombo GL; Recchia M; Ciriminna S;
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):322-9. PubMed ID: 19430343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporal changes in coronary revascularization procedures, outcomes, and costs in the bare-metal stent and drug-eluting stent eras: results from the US Medicare program.
    Ryan J; Linde-Zwirble W; Engelhart L; Cooper L; Cohen DJ
    Circulation; 2009 Feb; 119(7):952-61. PubMed ID: 19204307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of drug-eluting stents in coronary angioplasty.
    Santos R; Pereira H
    Rev Port Cardiol; 2005 Nov; 24(11):1409-18. PubMed ID: 16463989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.